131
Participants
Start Date
April 29, 2016
Primary Completion Date
April 11, 2023
Study Completion Date
April 11, 2023
Ocrelizumab
Ocrelizumab will be administered as IV infusion.
Lumbar Puncture
Participants will receive LP as specified in individual arms. Lumbar puncture is optional at week 52, except for RMS Cohort Arm 3 and PPMS Cohort. In addition, the lumbar punctures in the Long Term Extension phase is every other year.
Methyloprednisolone
Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
Antihistamine
Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.
Empire Neurology, PC, Latham
University of North Carolina at Chapel Hill, Chapel Hill
Universitätsmedizin Göttingen Georg-August-Universität, Göttingen
Ohio State University, Columbus
Washington University; Wash Uni. Sch. Of Med, St Louis
Weill Cornell MC-NY Presbyter; Dept. of Neurology/Neuroscience, Judith Jaffe Multiple Sclerosis Ctr, New York
Oklahoma Medical Research Foundation; MS Center of Excellence, Oklahoma City
University Of Colorado, Aurora
University of California at San Francisco, San Francisco
Stanford University, Palo Alto
Yale University School of Medicine ; Pulmonary & Critical Care, New Haven
University of Massachusetts Medical School, Worcester
University of Texas Southwestern Medical Center, Dallas
University of British Columbia Hospital Site; Djavad Mowafaghian Centre for Brain Health, Vancouver
McGill University; Montreal Neurological Institute; Neurological and Psychiatric, Montreal
"Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden", Dresden
Karolinska Universitetssjukhuset, Solna, Stockholm
Lead Sponsor
Genentech, Inc.
INDUSTRY